Wednesday, July 8, 2026

pharma · Fibromyalgia · Primary Fibromyalgia · TNXP

Tonix Pharmaceuticals Holding

Tonix Pharmaceuticals is a pharma organization headquartered in Berkeley Heights, USA. It trades on NYSE under ticker TNXP. Primary therapeutic focus areas include Fibromyalgia, Primary Fibromyalgia, PTSD, Acute Stress R

200 Connell Dr, Berkeley Heights, New Jersey 07922, US HQ
2007 Founded
154 Employees
Public company Type
TNXP · NYSE Ticker
Company details
Status
Public
HQ
200 Connell Dr, Berkeley Heights, New Jersey 07922, US
Founded
2007
Employees
154
Programs
30
Drugs
10
Patents
86
Clinical program

TNX-102 SL 5.6 mg

Phase 3 · small molecule · PTSD

TNX-102 SL 5.6 mg for PTSD is a Phase 3 program (small_molecule) at Tonix Pharmaceuticals Holding with 1 ClinicalTrials.gov record(s).

← All Tonix Pharmaceuticals Holding projects Phase 3 small molecule completed

Internal code TNX-CY-P306

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Tonix Pharmaceuticals Holding
Phase
Phase 3
Modality
small_molecule
Indication
PTSD
Status
completed
Trials
1

Clinical trials